Financial Performance - The company's operating revenue for Q1 2022 was ¥257,889,942.36, representing a 31.35% increase compared to ¥196,335,886.00 in the same period last year[4] - Net profit attributable to shareholders was ¥68,837,886.38, up 33.58% from ¥51,532,054.43 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥67,103,847.65, reflecting a 33.71% increase from ¥50,184,657.21 in the previous year[4] - Operating profit for the quarter was ¥82,643,519.25, representing a year-on-year increase of 34.4% from ¥61,442,743.98[32] - The net profit for the current period is 68,837,886.38, compared to 51,532,054.43 in the previous period, representing a growth of approximately 33.5%[35] - Basic earnings per share increased to 0.1637 from 0.1429, reflecting a rise of about 17.5%[35] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥25,565,492.63, a significant decrease of 243.49% compared to a net inflow of ¥17,817,167.60 in the same period last year[4] - Cash inflow from operating activities totaled 111,051,731.17, up from 104,546,329.66, indicating an increase of approximately 6.4%[39] - Cash outflow from operating activities rose to 136,617,223.80 from 86,729,162.06, resulting in a net cash flow from operating activities of -25,565,492.63, compared to 17,817,167.60 in the previous period[39] - The net increase in cash and cash equivalents for the current period was 102,426,479.43, compared to a decrease of -23,649,155.33 in the previous period[42] - The ending balance of cash and cash equivalents reached 303,024,322.61, up from 158,090,558.38, indicating a growth of approximately 91.5%[42] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,499,796,542.20, an increase of 5.43% from ¥1,422,613,681.07 at the end of the previous year[4] - Total liabilities amounted to ¥154,620,823.62, up from ¥147,569,613.39, reflecting a rise of 4.3%[24] - Non-current assets totaled ¥578,619,908.22, up from ¥526,091,085.17, showing a growth of 10%[24] - Cash and cash equivalents at the end of the period totaled ¥303,024,322.61, up from ¥200,597,843.18 at the beginning of the year, reflecting a 50.9% increase[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,073[12] - The largest shareholder, Huabang Life Health Co., Ltd., holds 44.51% of shares, totaling 187,216,000 shares[12] - The second-largest shareholder, Zibo Kaisheng Investment Management Center, holds 6.79% of shares, totaling 28,571,200 shares[12] - The company has a total of 364,305,348 shares, with 360,640,000 shares remaining under lock-up conditions[19] - The total number of shares held by the top ten shareholders includes significant stakes from various investment firms and individuals, indicating strong institutional support[12] Operational Developments - The company’s technology center was recognized as a national enterprise technology center in 2021[20] - The company is constructing a new production base in Weifang, which officially commenced on February 12, 2022[20] Other Expenses - The company reported a significant increase in sales expenses by 119.00% to ¥258,000, attributed to higher export business costs[7] - Other operating expenses increased by 196.43% to ¥95,140, primarily due to a donation of ¥1,000,000 to a charity for epidemic prevention[10] Share Issuance and Restrictions - The company has no new shares issued during the reporting period, maintaining the same number of restricted shares[16] - The company plans to lift restrictions on certain shares on September 27, 2022, and September 27, 2024, for various shareholders[16] - The company has not reported any changes in the number of restricted shares during the current period[19] Comprehensive Income - The company reported a total comprehensive income of 68,837,886.38, which is the same as the net profit, indicating no other comprehensive income items for the period[35] Audit Status - The company has not undergone an audit for the first quarter report[43]

Financial Performance - The company's operating revenue for 2021 was ¥879,591,549.14, representing a 40.95% increase compared to ¥624,026,860.13 in 2020[25] - The net profit attributable to shareholders for 2021 was ¥193,379,071.90, which is a 20.50% increase from ¥160,480,613.99 in 2020[25] - The net profit after deducting non-recurring gains and losses was ¥179,772,058.36, up 13.91% from ¥157,818,314.46 in 2020[25] - The total assets at the end of 2021 reached ¥1,422,613,681.07, a 57.40% increase from ¥903,824,701.09 at the end of 2020[25] - The net assets attributable to shareholders increased by 59.84% to ¥1,275,044,067.68 at the end of 2021 from ¥797,702,313.28 at the end of 2020[25] - The basic earnings per share for 2021 was ¥0.5148, reflecting a 15.69% increase from ¥0.4450 in 2020[25] - The net cash flow from operating activities decreased by 36.66% to ¥88,631,424.00 in 2021 from ¥139,935,143.91 in 2020[25] - The weighted average return on equity for 2021 was 20.04%, down from 22.04% in 2020[25] Revenue and Sales - The company's total revenue for Q4 was ¥278,042,348.33, showing a significant increase compared to Q1's ¥196,335,886.00[28] - The net profit attributable to shareholders for Q4 was ¥51,711,693.62, which is an increase from Q2's ¥43,433,707.18[28] - The net cash flow from operating activities in Q4 reached ¥38,378,596.53, a notable rise from Q1's ¥17,817,167.60[28] - Chlorosulfonic acid revenue reached CNY 295.93 million, accounting for 33.64% of total revenue, with a year-over-year growth of 63.72%[83] - Domestic sales contributed CNY 818.21 million, representing 93.02% of total revenue, with a year-over-year increase of 55.21%[86] Production and Capacity - The company is expanding its production capacity with the new Weifang production base and the mass market introduction of new products like polyether ketone[38] - The production capacity utilization rate for chlorosulfonic acid is 90.02%, with a designed capacity of 150,000 tons per year[67] - The company is in the industrial production stage for key products such as chlorosulfonic acid and aramid polymer monomer, with ongoing technology iterations[67] - The company has initiated trial production for a new project with a capacity of 10,000 tons per year for isophthaloyl chloride, which began in February 2022[69] - The company is expanding its production capabilities with a new project for high-purity 2-propoxyethyl chloride, which is currently in trial production[71] Research and Development - The company has a strong R&D team with 157 personnel, including 3 PhDs and 7 Master's degree holders, focusing on high-end chemical products and has 139 patents, of which 86 are invention patents[45] - The company has established various innovation platforms, including a national postdoctoral research station and a national enterprise technology center, enhancing its R&D capabilities[45] - The company is committed to continuous investment in new product development to ensure the commercialization of research outcomes[45] - The number of R&D personnel increased by 64.52% from 93 in 2020 to 153 in 2021, with R&D personnel accounting for 24.84% of the total workforce[104] - R&D investment amounted to ¥43,096,738.38 in 2021, representing 4.90% of operating revenue, an increase from 4.74% in 2020[104] Market and Sales Strategy - The company has established strong relationships with key clients, including DuPont and Teijin, enhancing its market presence in regions such as China, Japan, South Korea, and the United States[81] - The company is focused on optimizing its production processes and has developed a circular economy model for sulfur dioxide, reducing environmental impact and production costs[78] - The company aims to establish a comprehensive industrial chain from basic chemical raw materials to high-performance polymer materials, targeting four downstream industries: new pigments, new pesticides, new materials, and new energy[140] - The company plans to enhance its product structure and increase production capacity for core products while improving product quality and reducing energy consumption[141] Financial Management - The total investment amount during the reporting period was ¥10,500,000, a 100% increase compared to the same period last year[118] - The company made a significant equity investment of ¥10,500,000 in Shandong Research Institute of High-Performance Materials, acquiring a 35% stake[118] - The company reported a loss of ¥133,678.88 from the investment in Shandong Research Institute of High-Performance Materials[118] - The total amount of raised funds was ¥31,020,000, with ¥4,277,100 utilized during the reporting period[123] - The remaining unused raised funds amount to ¥24,008,320, which are temporarily managed as cash[123] Governance and Compliance - The company has established an internal control system to manage risks and ensure normal business operations[154] - The company maintains transparency in information disclosure, adhering to relevant regulations and ensuring fair access to information for all shareholders[155] - The actual controller of the company exercises rights and obligations without occupying company funds or exceeding authority[151] - The company has no significant differences in governance compared to regulations set by the China Securities Regulatory Commission[158] - The company has a complete and independent business operation capability, independent of the controlling shareholder[159] Employee and Management - The total number of employees at the end of the reporting period was 616[199] - The management team includes professionals with advanced degrees and certifications, such as senior engineers and accountants, ensuring a high level of expertise[170] - The company has appointed independent directors with significant experience in finance and law, enhancing governance and oversight[171] - The total remuneration for directors, supervisors, and senior management in 2021 amounted to CNY 5.4499 million, which is linked to their positions and performance evaluations[180] - Wang Jiarong, the Chairman and General Manager, received a pre-tax total remuneration of CNY 1.6483 million in 2021[183]

Financial Performance - The company's revenue for Q3 2021 reached ¥202,105,971.97, an increase of 41.91% compared to the same period last year[5] - Net profit attributable to shareholders was ¥46,701,616.67, reflecting a growth of 33.26% year-over-year[5] - The net profit after deducting non-recurring gains and losses was ¥40,422,697.94, up by 22.69% compared to the previous year[5] - Total operating revenue for the period reached ¥601,549,200.81, an increase of 28.8% compared to ¥466,806,957.24 in the previous period[34] - Net profit for the period was ¥141,667,378.28, slightly higher than ¥140,860,635.38 in the previous period, indicating stable profitability[37] - The company's basic earnings per share for Q3 2021 was ¥0.1295, up 33.23% from the same period last year[5] - The basic earnings per share for the period was ¥0.3928, compared to ¥0.3906 in the previous period, showing slight growth in earnings per share[40] - The company reported a profit margin of approximately 23.5% for the period, consistent with previous performance levels[34] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,341,124,701.70, representing a 48.38% increase from the end of the previous year[8] - Total assets rose to ¥1,341,124,701.70, compared to ¥903,824,701.09 in the previous period, showing strong growth in asset base[33] - Total liabilities increased to ¥117,884,758.46 from ¥106,122,387.81, indicating a rise in financial obligations[33] - Shareholders' equity attributable to the parent company reached ¥1,223,239,943.24, a rise of 53.35% year-over-year[8] - The company's equity attributable to shareholders reached ¥1,223,239,943.24, up from ¥797,702,313.28, reflecting improved shareholder value[33] Cash Flow - The company's cash flow from operating activities showed a significant decline of 59.31%, totaling ¥50,252,827.47 year-to-date[5] - Operating cash inflow for the current period was CNY 335,201,262.53, a decrease of 4.0% compared to CNY 351,551,359.76 in the previous period[41] - Operating cash outflow totaled CNY 284,948,435.06, an increase of 25.0% from CNY 228,056,590.17 in the previous period[44] - Net cash flow from operating activities was CNY 50,252,827.47, down 59.3% from CNY 123,494,769.59 in the previous period[44] - Cash inflow from investment activities was CNY 437,153,817.85, up 52.5% from CNY 286,613,209.48 in the previous period[44] - Net cash flow from investment activities was -CNY 166,409,877.76, worsening from -CNY 94,752,965.20 in the previous period[44] - Cash inflow from financing activities was CNY 290,754,716.98, with no previous period data available[44] - Net cash flow from financing activities was CNY 290,754,716.98, compared to -CNY 98,049,000.00 in the previous period[44] - The net increase in cash and cash equivalents was CNY 174,509,114.32, contrasting with a decrease of -CNY 69,649,851.29 in the previous period[44] - The ending balance of cash and cash equivalents was CNY 356,248,828.03, up from CNY 179,277,897.34 in the previous period[44] Research and Development - Research and development expenses increased by 47.1% year-over-year, amounting to an additional ¥805.12 million[14] - Research and development expenses increased to ¥25,145,928.14 from ¥17,094,689.53, highlighting a focus on innovation[37] Shareholder Information - The company reported a total of 364,305,348 shares with restrictions as of the end of the reporting period[24] - The number of unrestricted shares held by the top ten shareholders totaled 27,180,308 shares, with the largest shareholder holding 187,216,000 shares[20] - The company has no new restricted shares added during the reporting period, maintaining the same number of restricted shares[24] Inventory and Current Assets - The total current assets as of September 30, 2021, amounted to CNY 883,389,168.84, an increase from CNY 548,764,240.80 as of December 31, 2020, reflecting a growth of approximately 60.8%[27] - Cash and cash equivalents increased to CNY 356,249,128.03 from CNY 181,739,713.71, representing a growth of about 96% year-over-year[27] - Accounts receivable rose to CNY 69,077,680.52 from CNY 56,731,306.02, indicating an increase of approximately 21.8%[27] - The total inventory as of September 30, 2021, was CNY 33,478,588.89, up from CNY 22,946,355.08, marking an increase of approximately 46%[27] - The company’s long-term equity investments were valued at CNY 10,498,067.95 as of September 30, 2021[27] - The fixed assets increased to CNY 258,470,154.59 from CNY 216,486,048.36, reflecting a growth of about 19.4%[27] Other Information - The company has not disclosed any new strategies or future outlook in the provided documents[25] - The report for the third quarter was not audited[47]